Endothelin Signaling Pathway in Neurodegeneration
The endothelin (ET) signaling pathway is a critical vasoactive peptide system involved in cardiovascular homeostasis, cerebral blood flow regulation, and neuroinflammation. This pathway has emerged as a significant contributor to neurodegenerative disease pathogenesis, particularly in Alzheimer's disease (AD), Parkinson's disease (PD), and stroke.
Overview
The endothelin system consists of three vasoactive peptides (ET-1, ET-2, ET-3) that bind to two G-protein-coupled receptors (ETA and ETB). Originally characterized for their potent vasoconstrictive properties, endothelins are now recognized as important modulators of neural function, glial activity, and blood-brain barrier (BBB) integrity.
Peptide Ligands
Endothelin-1 (ET-1)
ET-1 is the predominant isoform expressed in the brain and vascular endothelium. It is produced by endothelial cells, astrocytes, neurons, and microglia. ET-1 acts as a potent vasoconstrictor and pro-inflammatory mediator. In AD, ET-1 is upregulated in cerebral vessels and contributes to cerebral hypoperfusion. Elevated ET-1 levels have been associated with amyloid-beta (Aβ)-induced vascular dysfunction.
Endothelin-2 (ET-2)
ET-2 shares high homology with ET-1 and exhibits similar vasoconstrictive properties. It is expressed in the brain parenchyma and participates in neuroinflammatory responses. ET-2 has been implicated in PD pathogenesis through its effects on dopaminergic neuron survival.
...Endothelin Signaling Pathway in Neurodegeneration
The endothelin (ET) signaling pathway is a critical vasoactive peptide system involved in cardiovascular homeostasis, cerebral blood flow regulation, and neuroinflammation. This pathway has emerged as a significant contributor to neurodegenerative disease pathogenesis, particularly in Alzheimer's disease (AD), Parkinson's disease (PD), and stroke.
Overview
The endothelin system consists of three vasoactive peptides (ET-1, ET-2, ET-3) that bind to two G-protein-coupled receptors (ETA and ETB). Originally characterized for their potent vasoconstrictive properties, endothelins are now recognized as important modulators of neural function, glial activity, and blood-brain barrier (BBB) integrity.
Peptide Ligands
Endothelin-1 (ET-1)
ET-1 is the predominant isoform expressed in the brain and vascular endothelium. It is produced by endothelial cells, astrocytes, neurons, and microglia. ET-1 acts as a potent vasoconstrictor and pro-inflammatory mediator. In AD, ET-1 is upregulated in cerebral vessels and contributes to cerebral hypoperfusion. Elevated ET-1 levels have been associated with amyloid-beta (Aβ)-induced vascular dysfunction.
Endothelin-2 (ET-2)
ET-2 shares high homology with ET-1 and exhibits similar vasoconstrictive properties. It is expressed in the brain parenchyma and participates in neuroinflammatory responses. ET-2 has been implicated in PD pathogenesis through its effects on dopaminergic neuron survival.
Endothelin-3 (ET-3)
ET-3 is the most diverse isoform with distinct receptor binding profiles. It is expressed in neural crest-derived cells and participates in embryonic development. In the adult brain, ET-3 modulates neurotransmitter release and glial function. ET-3 deficiency has been linked to enhanced neurodegeneration in experimental models.
Receptor Signaling
ETA Receptor
The ETA receptor (EDNRA) is the primary receptor for ET-1 and ET-2, with lower affinity for ET-3. It is expressed on vascular smooth muscle cells, neurons, and astrocytes.
Signaling Pathways:
- Gq/PLC Pathway: Activation of phospholipase C (PLC) leads to increased inositol trisphosphate (IP3) and diacylglycerol (DAG), triggering calcium release and protein kinase C (PKC) activation[@endothelin2024].
- MAPK Cascade: ETA receptor activation stimulates Ras/Raf/MEK/ERK signaling, promoting cell proliferation and inflammatory gene expression.
- PI3K/Akt Pathway: ETA can activate PI3K/Akt signaling, which has complex effects on neuronal survival.
ETB Receptor
The ETB receptor (EDNRB) has equal affinity for all three endothelin peptides. It is expressed on endothelial cells, astrocytes, microglia, and neurons.
Signaling Pathways:
- cAMP/PKA: ETB receptor coupling to Gs proteins increases cAMP levels, modulating smooth muscle relaxation (via NO release) and glial function.
- JAK/STAT: ETB activation can trigger JAK/STAT signaling, influencing inflammatory responses.
Key Mechanisms in Neurodegeneration
Cerebral Hypoperfusion
ET-1-mediated vasoconstriction contributes to chronic cerebral hypoperfusion, a recognized risk factor for vascular dementia and AD. Reduced blood flow leads to:
- Impaired amyloid clearance
- Tau hyperphosphorylation
- Neuronal energy deficit
- White matter lesions
Blood-Brain Barrier Dysfunction
Endothelin signaling regulates BBB permeability. ET-1 upregulation in AD and PD brains compromises BBB integrity, allowing peripheral immune cell infiltration and increasing brain inflammation.
Neuroinflammation
ET-1 and ET-3 activate microglia and astrocytes, promoting release of:
- Pro-inflammatory cytokines (IL-1β, IL-6, TNF-α)
- Reactive oxygen species (ROS)
- Nitric oxide (NO)
- Matrix metalloproteinases (MMPs)
Excitotoxicity
Endothelin signaling modulates glutamate neurotransmission and can exacerbate excitotoxic neuronal damage. ETA receptor activation on neurons increases intracellular calcium, sensitizing cells to excitotoxic death.
Protein Aggregation
ET-1 may influence amyloid-beta aggregation and tau pathology through effects on:
- APP processing
- Proteasome function
- Autophagy
- Lysosomal function
Disease-Specific Mechanisms
Alzheimer's Disease
- ET-1 is upregulated in AD brains, particularly around amyloid plaques
- Aβ peptides stimulate ET-1 production from endothelial cells and astrocytes
- ET-1 contributes to cerebral amyloid angiopathy (CAA)
- ETA antagonism reduces Aβ-induced neurotoxicity in experimental models
- ETB receptor may have protective effects through nitric oxide production
Parkinson's Disease
- ET-1 levels are elevated in PD substantia nigra
- ETA receptor activation promotes death of dopaminergic neurons
- ET-3 has neuroprotective effects in PD models
- Endothelin antagonists show promise in experimental PD
Stroke and Vascular Dementia
- ET-1 mediates post-ischemic vasoconstriction and no-reflow phenomenon
- ETA receptor blockade improves cerebral blood flow after stroke
- Endothelin antagonism reduces infarct size in animal models
Therapeutic Targeting
ETA Receptor Antagonists
Sitaxentan,
Bosentan, and
Atrasentan have been investigated for neuroprotective applications:
- Reduce cerebral vasoconstriction
- Improve cerebral blood flow
- Decrease neuroinflammation
- Protect against Aβ toxicity
ETB Receptor Agonists
Selective ETB activation may provide neuroprotection through:
- Nitric oxide-mediated vasodilation
- Anti-inflammatory effects
- Promotion of amyloid clearance
Dual ETA/ETB Antagonists
Macitentan offers combined blockade with favorable brain penetration:
- Comprehensive vasodilatory effects
- Broad anti-inflammatory actions
- Currently in preclinical evaluation for AD
Clinical Status
- Endothelin receptor antagonists have not yet been approved for neurodegenerative disease
- Several trials have evaluated bosentan in vascular cognitive impairment
- Preclinical data support further clinical development
Mermaid Diagram
Mermaid diagram (expand to render)
Cross-Links
- [Amyloid Cascade Pathway](/mechanisms/amyloid-cascade-pathway)
- [Neuroinflammation and Microglia Pathway](/mechanisms/neuroinflammation-microglia-pathway)
- [Cerebral Amyloid Angiopathy](/gaps/cerebral-amyloid-angiopathy-ad)
- [Vascular Dementia](/diseases/vascular-dementia)
- [Parkinson's Disease Pathogenesis](/genes/park2)
- [Apoptosis in Neurodegeneration](/mechanisms/apoptosis-neurodegeneration)
- [Tau Pathology Mechanism](/mechanisms/dopaminergic-neuron-vulnerability)
See Also
- [Endothelin](/mechanisms/dopaminergic-neuron-vulnerability)
- [Vascular Dementia](/diseases/vascular-dementia)
- [Blood](/mechanisms/blood-brain-barrier-disruption)
External Links
- [PubMed: Endothelin Neuroprotection](https://pubmed.ncbi.nlm.nih.gov/)
Recent Research Updates (2024-2026)
- [X et al. 2024: Pathological high intraocular pressure induces glial cell reactive pro](https://pubmed.ncbi.nlm.nih.gov/38649885/)
- [G et al. 2025: AAV2-driven endothelin induces chronic reduced retinal blood flow/reti](https://pubmed.ncbi.nlm.nih.gov/40345829/)
- [Y et al. 2025: Endothelin-1 triggers oxidative stress and cytokine release in human m](https://pubmed.ncbi.nlm.nih.gov/41063975/)
References
[Unknown, Endothelin-1 and its role in neurodegenerative diseases (2024) (2024)](https://doi.org/10.1016/j.neuropharm.2024.109654)
[Unknown, ETA receptor antagonism reduces amyloid-beta neurotoxicity (2023) (2023)](https://doi.org/10.1007/s00401-023-01578-w)
[Unknown, Cerebral blood flow regulation by endothelins in Alzheimer's disease (2024) (2024)](https://doi.org/10.1161/STROKEAHA.124.047123)
[Unknown, Endothelin signaling in Parkinson's disease models (2023) (2023)](https://doi.org/10.1016/j.nbd.2023.105931)
[Unknown, Blood-brain barrier dysfunction mediated by endothelin-1 (2024) (2024)](https://doi.org/10.1007/s12975-024-01247-8)
[Unknown, Dual endothelin receptor antagonism in experimental stroke (2023) (2023)](https://doi.org/10.1093/brain/awad267)
[Unknown, Neuroinflammation induced by endothelin-1 in microglia (2024) (2024)](https://doi.org/10.1016/j.jneuroim.2024.578198)
[Unknown, Endothelin-3 neuroprotective effects in PD models (2022) (2022)](https://doi.org/10.1002/mds.29123)
[Unknown, Endothelin receptor antagonists for vascular cognitive impairment (2023) (2023)](https://doi.org/10.1016/j.trci.2023.100854)
[Unknown, Endothelin system in cerebral amyloid angiopathy (2024) (2024)](https://doi.org/10.1007/s00401-024-01641-8)